Great Point Partners LLC Travere Therapeutics, Inc. Transaction History

Great Point Partners LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $14.4 Million - $21.3 Million	-943,000 Reduced 94.02%	60,000 $921,000
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $9.41 Million - $12.1 Million	528,000 Added 111.16%	1,003,000 $22.6 Million
Q4 2022 Feb 14, 2023	SELL	$18.47 - $26.14 $9.07 Million - $12.8 Million	-491,108 Reduced 50.83%	475,000 $9.99 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $117,413 - $146,728	-5,125 Reduced 0.53%	966,108 $23.8 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $811,780 - $1.16 Million	-38,767 Reduced 3.84%	971,233 $23.5 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $4.96 Million - $6.43 Million	210,000 Added 26.25%	1,010,000 $26 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $4.26 Million - $5.45 Million	175,000 Added 28.0%	800,000 $24.8 Million
Q3 2021 Nov 15, 2021	SELL	$12.98 - $25.03 $5.96 Million - $11.5 Million	-459,300 Reduced 42.36%	625,000 $15.2 Million
Q2 2021 Aug 16, 2021	BUY	$14.11 - $26.4 $6.92 Million - $13 Million	490,588 Added 82.63%	1,084,300 $15.8 Million
Q1 2021 May 17, 2021	BUY	$23.37 - $31.77 $13.9 Million - $18.9 Million	593,712 New	593,712 $14.8 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.